Home > Insider Trading > Filing (0000899243-20-020683)

Filing Details

Accession Number:: 0000899243-20-020683
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-29 21:18:46
Reporting Period:: 2020-07-28

Accepted Time:: 2020-07-29 21:18:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1134657	Luke Evnin	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1473930	Todd Foley	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609492	Mpm Bioventures 2014, L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609493	Mpm Bioventures 2014 (B), L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1609495	Mpm Asset Management Investors Bv2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1729504	Mpm Bioventures 2018 (B), L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1729505	Mpm Bioventures 2018, L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1734817	Mpm Asset Management Investors Bv2018 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765021	Mpm Bioventures 2014 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1765091	Mpm Bioventures 2014 Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-28	1,269,230	$0.00	1,269,230	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	84,655	$0.00	84,655	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	43,687	$0.00	43,687	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	801,619	$0.00	801,619	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	42,605	$0.00	42,605	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	15,820	$0.00	15,820	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	724,702	$0.00	1,993,932	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	48,336	$0.00	132,991	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	24,944	$0.00	68,381	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	457,706	$0.00	1,259,325	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	24,326	$0.00	66,931	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	9,033	$0.00	24,853	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	89,955	$19.00	2,083,887	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	5,994	$19.00	138,985	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	3,096	$19.00	71,727	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	56,814	$19.00	1,316,139	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	3,020	$19.00	69,951	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-07-28	1,121	$19.00	25,974	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	3,824,591	$0.00	1,269,230	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	255,094	$0.00	84,655	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	131,645	$0.00	43,687	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	2,415,530	$0.00	801,619	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	128,384	$0.00	42,605	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-28	47,674	$0.00	15,820	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	2,361,805	$0.00	724,702	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	157,529	$0.00	48,336	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	81,295	$0.00	24,944	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	1,491,666	$0.00	457,706	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	79,281	$0.00	24,326	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2020-07-28	29,440	$0.00	9,033	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering.
(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC.
MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC.
Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
On July 28, 2020, BV 2014 purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2014(B) purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2018 purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, BV 2018(B) purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.
On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering.